BioTelemetry Inc. (NASDAQ:BEAT) shot up 1.7% during mid-day trading on Tuesday . The stock traded as high as $17.86 and last traded at $17.67, with a volume of 310,488 shares traded. The stock had previously closed at $17.37.

Separately, Zacks Investment Research cut BioTelemetry from a “hold” rating to a “sell” rating in a report on Tuesday, April 19th.

The company has a market cap of $492.89 million and a P/E ratio of 44.73. The firm has a 50 day moving average of $16.53 and a 200 day moving average of $13.34.

BioTelemetry (NASDAQ:BEAT) last released its earnings results on Tuesday, April 26th. The company reported $0.20 EPS for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.10. During the same period last year, the firm earned $0.06 EPS. The firm had revenue of $48.60 million for the quarter, compared to analyst estimates of $46.54 million. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. Equities analysts predict that BioTelemetry Inc. will post $0.71 EPS for the current fiscal year.

A number of hedge funds and institutional investors recently made changes to their positions in BEAT. Royce & Associates LLC boosted its position in shares of BioTelemetry by 102.2% in the fourth quarter. Royce & Associates LLC now owns 606,700 shares of the company’s stock valued at $7,086,000 after buying an additional 306,700 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of BioTelemetry by 13.6% in the fourth quarter. Wells Fargo & Company MN now owns 994,163 shares of the company’s stock valued at $11,612,000 after buying an additional 119,328 shares in the last quarter. Gabelli Funds LLC bought a new position in shares of BioTelemetry during the fourth quarter valued at $1,190,000. Dimensional Fund Advisors LP boosted its position in shares of BioTelemetry by 8.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,317,266 shares of the company’s stock valued at $15,386,000 after buying an additional 98,737 shares in the last quarter. Finally, Russell Frank Co boosted its position in shares of BioTelemetry by 58.9% in the fourth quarter. Russell Frank Co now owns 249,457 shares of the company’s stock valued at $2,933,000 after buying an additional 92,455 shares in the last quarter.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.